Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
104 USD | +1.28% |
|
+1.53% | +4.00% |
06-24 | Foreign banks target Switzerland after UBS takeover of Credit Suisse | RE |
06-24 | NOVARTIS AG : Barclays reaffirms its Sell rating | ZD |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Sales forecast by analysts have been recently revised upwards.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's earnings growth outlook lacks momentum and is a weakness.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+4.00% | 218B | - | ||
+55.32% | 815B | C+ | ||
+44.05% | 641B | B | ||
-6.75% | 352B | C+ | ||
+13.56% | 314B | B- | ||
+10.68% | 303B | C+ | ||
+16.57% | 242B | B+ | ||
+8.48% | 168B | C+ | ||
-2.81% | 159B | C+ | ||
+0.20% | 120B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- NOVN Stock
- NVSEF Stock
- Ratings Novartis AG